Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

November 11, 2019November 11, 2019

Blood Protein Levels Linked to Disease Activity in Children with SLE and May Be Biomarkers, Study Reports

News

Levels of proteins associated with changes in the inner wall of blood vessels — the endothelium — are higher in children and adolescents with systemic lupus erythematosus (SLE) and ... Read more

November 4, 2019November 4, 2019

Using Hydroxychloroquine for Less Than 1 Year Raises Patients’ Likelihood of Flares, Study Suggests

News

People with systemic lupus erythematosus (SLE) who stop treatment with hydroxychloroquine less than 12 months after its start are at a higher risk of flares than those who continue ... Read more

October 30, 2019December 5, 2019

More Than 40% of SLE Patients Do Not Adhere to Hydroxychloroquine Therapy, Study Reports

News

More than 40% of systemic lupus erythematosus (SLE) patients do not comply with hydroxychloroquine (HCQ) therapy, even among people who have insurance coverage, low copayments, and availability of high ... Read more

October 28, 2019October 28, 2019

Phase 3 Trial of Voclosporin for Lupus Nephritis Completes Study Visits, Results Expected Soon

News

A Phase 3 trial assessing the potential of voclosporin as an add-on to standard treatment for people with lupus nephritis has completed patient visits. “With the completion of patient ... Read more

October 21, 2019

Apellis Stopping Development of APL-2 for Lupus Nephritis After Completion of Phase 2 Trial

News

Apellis Pharmaceuticals has decided to stop the development of an experimental therapy known as APL-2 for lupus nephritis and primary membranous nephropathy after the completion of an ongoing Phase ... Read more

October 7, 2019October 21, 2019

‘Lupus Low Disease Activity State’ Protects Patients Against Flares, Organ Damage, Study Suggests

News

Patients with systemic lupus erythematosus (SLE) who attain a low disease state have a lower risk of subsequent disease flares and accumulated organ damage, making this state a potential ... Read more

September 13, 2019September 13, 2019

CARRA Granted $2.4M for Research Efforts to Determine Lifetime Outcomes of Children and Adolescents with Lupus

News

The Childhood Arthritis and Rheumatology Research Alliance (CARRA) has been awarded a three-year $2.4-million grant from the U.S. Centers for Disease Control and Prevention (CDC), which will help efforts ... Read more

July 31, 2019August 26, 2019

Progentec Granted $1.7M to Validate Measure of SLE Disease Activity

News

Progentec, a company developing new diagnostic technologies for chronic conditions, has been awarded $1.7 million to validate its blood biomarker test as an accurate tool for measuring disease activity ... Read more

July 29, 2019

‘Lupus Low Disease Activity State’ Linked to Reduced Healthcare Costs, Study Confirms

News

Attaining a low disease state — deemed Lupus Low Disease Activity State or LLDAS — has become a major goal for treatment for people with systemic lupus erythematosus. Researchers ... Read more

July 8, 2019

Lupus Research Alliance, Bristol-Myers Join to Advance Phase 2 Study of Oral Treatment for Lupus Nephritis

News

The Lupus Research Alliance (LRA) and its affiliate Lupus Therapeutics have expanded a collaboration with Bristol-Myers Squibb to help assess the company’s investigational agent BMS-986165 as a possible treatment for lupus ... Read more

This is a short description about myself and what this site is about. I hope you enjoy being here!

Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Blood Protein Levels Linked to Disease Activity in Children with SLE and May Be Biomarkers, Study Reports

Using Hydroxychloroquine for Less Than 1 Year Raises Patients’ Likelihood of Flares, Study Suggests

More Than 40% of SLE Patients Do Not Adhere to Hydroxychloroquine Therapy, Study Reports

Phase 3 Trial of Voclosporin for Lupus Nephritis Completes Study Visits, Results Expected Soon

Apellis Stopping Development of APL-2 for Lupus Nephritis After Completion of Phase 2 Trial

‘Lupus Low Disease Activity State’ Protects Patients Against Flares, Organ Damage, Study Suggests

CARRA Granted $2.4M for Research Efforts to Determine Lifetime Outcomes of Children and Adolescents with Lupus

Progentec Granted $1.7M to Validate Measure of SLE Disease Activity

‘Lupus Low Disease Activity State’ Linked to Reduced Healthcare Costs, Study Confirms

Lupus Research Alliance, Bristol-Myers Join to Advance Phase 2 Study of Oral Treatment for Lupus Nephritis

Pin It on Pinterest